Second Department of Radiotherapy, Yantaishan Hospital, Yantai, China.
Department of Traditional Chinese Medicine, Yantai Food and Drug Inspection and Testing Center, Yantai, 264003, China
Bioengineered. 2021 Dec;12(2):12931-12939. doi: 10.1080/21655979.2021.2012620.
This study aims to investigate the potential clinical function of long non-coding RNA CERS6-AS1 (lncRNA CERS6-AS1) integrated miR-567 in gastric cancer. The expression of CERS6-AS1 in gastric cancer tissues was detected through RT-qPCR in contrast to the normal tissues. The correlation between the expression of lncRNA CERS6-AS1 and the characteristics of clinical data was analyzed. Kaplan-Meier curve was used to assess the survival analysis, while Cox proportional hazards model multivariate analysis was performed to evaluate the prognostic risk factors of gastric cancer to verify the prognostic possibility of CERS6-AS1. The expression of CERS6-AS1 in different gastric cancer cells was detected, being the development of gastric cancer cells after knockdown CERS6-AS1 studied using CCK-8, Transwell migration, and invasion detection methods. The targeting effect and interaction between CERS6-AS1 and miR-567 through biological analysis and luciferase activity detection. The expression of lncRNA CERS6-AS1 was elevated in gastric cancer tissues and cells. The results of this study demonstrate that the condition of gastric cancer patients was related to the expression of CERS6-AS1, and therefore CERS6-AS1 might be a prognostic factor for the progression of gastric cancer. In addition, the ability of gastric cancer cells to proliferate, migrate and invade could be reduced by knockdown CERS6-AS1. After CERS6-AS1 knockdown, the expression level of miR-567 in gastric cancer tissues decreased, while the expression level of miR-567 increased. In conclusion, lncRNA CERS6-AS1 might promote the progression of gastric cancer and had the potential as a prognostic marker of gastric cancer.
本研究旨在探讨长链非编码 RNA CERS6-AS1(lncRNA CERS6-AS1)与 miR-567 整合在胃癌中的潜在临床功能。通过 RT-qPCR 检测胃癌组织中 CERS6-AS1 的表达情况,并与正常组织进行对比。分析 lncRNA CERS6-AS1 的表达与临床资料特征之间的相关性。采用 Kaplan-Meier 曲线进行生存分析,通过 Cox 比例风险模型多因素分析评估胃癌的预后危险因素,以验证 CERS6-AS1 的预后可能性。检测不同胃癌细胞中 CERS6-AS1 的表达情况,通过敲低 CERS6-AS1 研究胃癌细胞的发展情况,采用 CCK-8、Transwell 迁移和侵袭检测方法。通过生物分析和荧光素酶活性检测,对 CERS6-AS1 与 miR-567 之间的靶向作用和相互作用进行验证。结果表明,lncRNA CERS6-AS1 在胃癌组织和细胞中呈高表达。本研究结果表明,胃癌患者的病情与 CERS6-AS1 的表达有关,因此 CERS6-AS1 可能是胃癌进展的预后因素。此外,敲低 CERS6-AS1 可降低胃癌细胞的增殖、迁移和侵袭能力。敲低 CERS6-AS1 后,胃癌组织中 miR-567 的表达水平降低,而 miR-567 的表达水平升高。综上所述,lncRNA CERS6-AS1 可能促进胃癌的进展,并具有作为胃癌预后标志物的潜力。